Roche Farma

Name

Roche Farma

Legal name

Roche Farma, S.A.

Website

https://roche.es

Company type

Private

Founded year

1896

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Medical Oncology (HLAKAFAB), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Prescription pharmaceuticals
• Innovative oncology medicines
• Diagnostic systems reagents
• Clinical laboratory automation
• Personalized healthcare solutions

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Pharmaceutical Products (Prescription Medicines): Roche Farma generates revenue from the sale of innovative prescription medicines across oncology, neuroscience, hematology, and ophthalmology, distributed to hospitals and healthcare professionals through its field sales organization.
2. Diagnostic Systems and Reagents: Roche Diagnostics sells and supplies high-tech diagnostic systems, reagents, and services to clinical laboratories, research centers, physician offices, pharmacies, and for patient self-monitoring, generating recurring consumable revenue.
3. Healthcare Professional Portal (Roche+): A digital platform for healthcare professionals providing updated drug information, pathology resources, and professional interest materials, serving as a digital engagement channel.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels9 records

Core offering

Roche Farma develops, manufactures, and commercializes innovative prescription medicines across oncology (breast, lung, and hematological cancers), neuroscience (multiple sclerosis, spinal muscular atrophy, Alzheimer's), hematology, and ophthalmology (AMD, diabetic macular edema), distributed to hospitals and healthcare professionals through field sales representatives in Spain. Through its sister entity Roche Diagnostics, it supplies high-tech diagnostic systems, reagents, and laboratory services to clinical laboratories, research centers, physician offices, and pharmacies, integrating pharmaceutical and diagnostic capabilities to support personalized healthcare.

Product overview

Roche Farma operates as a pharmaceutical and diagnostics company in Spain, offering a dual portfolio comprising innovative medications across oncology (breast cancer, lung cancer, lymphoma), neuroscience (multiple sclerosis, Alzheimer's), hematology, and ophthalmology, alongside Roche Diagnostics' high-tech diagnostic systems, reagents, and services for clinical laboratories, research centers, physician offices, and patient self-monitoring. The company provides patient-facing portals (Rocheplus.es for healthcare professionals, rochepacientes.es for patients) and operates customer service platforms including Roche DiaLog for diagnostics clients. The portfolio includes specific diagnostic instruments like the cobas LIAT PCR system and the Harmony Prenatal Test.

Differentiator

Problem solved

Functional benefit

Brands

• Roche+ (rocheplus.es): Portal for healthcare professionals with updated information on drugs, pathologies and professional resources.
• Roche Pacientes (rochepacientes.es)
• Diálogos PHC
• Medicina por un Tubo

Products and services

• Roche Farma Innovative Pharmaceuticals Innovative prescription medicines across oncology (breast cancer, lung cancer, lymphoma), neuroscience (multiple sclerosis, spinal muscular atrophy, Alzheimer's), hematology, and ophthalmology, distributed to Spanish hospitals and healthcare professionals.
• Roche Diagnostics Systems, Reagents, and Services High-tech diagnostic systems, reagents, and laboratory services for clinical laboratories, research centers, physician offices, pharmacies, and patient self-monitoring, including recurring consumables and service revenue.
• cobas LIAT PCR System Rapid, easy-to-use PCR system for point-of-care use by clinicians, pharmacies, hospitals, and satellite laboratories, with one of two global repair centers hosted at the Sant Cugat site.
• Harmony Prenatal Test Non-invasive prenatal testing solution for chromosomal analysis, accessed through the contact form on the Roche España website.
• Roche DiaLog Customer Service Platform Online customer service area for Roche Diagnostics clients to access service requests, support, and account management.

Quantifiable outcome

• Giredestrant significantly reduced tumor proliferation without suppressing ovarian function in premenopausal women with early-stage ER+/HER2- breast cancer (EMPRESS study results)
• +2 more outcomes

Named customers5 records

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• FELUPUS (Federación Española de Lupus)coreStrategic or Co-development PartnerRoche collaborates with FELUPUS on the 'Hablando sin filtros' campaign to raise awareness and answer questions about lupus and lupus nephritis, with participation from medical specialists.
• AEACAP (Asociación Española de Afectados de Cáncer de Pulmón)coreStrategic or Co-development PartnerRoche collaborates with AEACAP to support lung cancer patients and raise awareness about the disease. Bernard Gaspar, president of AEACAP, participates in Roche's 'Medicina por un Tubo' podcast to share patient perspectives.
• FEDER (Federación Española de Enfermedades Raras)coreStrategic or Co-development PartnerRoche partners with FEDER on the podcast '¿Qué son las enfermedades raras?' featuring FEDER president Juan Carrión to educate about rare diseases.
• SERV (Sociedad Española de Retina y Vítreo)coreStrategic or Co-development PartnerThe 'La Mejor Vista Posible' series has the endorsement of SERV, bringing together retinologists and hospital pharmacists to discuss retinal disease treatment across Spanish cities.
• FEDE (Federación Española de Diabetes)minorStrategic or Co-development PartnerRoche collaborated with FEDE on a survey about diabetic macular edema (EMD) knowledge and perception among people with diabetes in Spain, collecting over 800 responses.
• FundAME (Fundación Atrofia Muscular España)minorStrategic or Co-development PartnerRoche and FundAME collaborated to produce patient stories about spinal muscular atrophy (SMA), giving visibility to the disease through real patient experiences.
• MovistarminorGTM or Marketing PartnerRoche collaborated with Movistar on the documentary 'Ensayo sobre la Mirada' (Essay on the Gaze), a human and emotional experiment inviting a new perspective on ophthalmology.
• Fundación Instituto RochecoreStrategic or Co-development PartnerThe Roche Foundation in Spain, based at the Madrid headquarters, works to promote research and innovation in healthcare and personalized medicine.
• Universidad Politécnica de ValenciaminorStrategic or Co-development PartnerRoche supports the 'Aula Roche UPV' initiative promoting personalized medicine education in collaboration with the Polytechnic University of Valencia.
• Esclerosis Múltiple España (EME)coreStrategic or Co-development PartnerRoche collaborates with EME on patient perspectives in personalized medicine discussions, including participation of EME director Pedro Carrascal in the Diálogos PHC series.
• BYD (Build Your Dreams)minorStrategic or Co-development PartnerGenentech (a member of the Roche Group) partnered with BYD to deploy electric buses as part of its zero-emissions fleet program, with BYD as the manufacturer of electric buses.
• Fundación ONCEminorStrategic or Co-development PartnerRoche donates second-life computer equipment to Fundación ONCE's initiatives supporting people with disabilities, as part of its circular economy and inclusion commitment.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bristol-Myers Squibb España: Spanish subsidiary of BMS with oncology (Opdivo, Yervoy) and hematology (Reblozyl, Pomalyst) franchises. Direct competitor to Roche Farma in lymphoma, multiple myeloma, and solid tumor oncology.
• MSD España (Merck & Co.): Spanish subsidiary of MSD with Keytruda-led oncology franchise competing head-to-head with Roche's checkpoint inhibitor and oncology portfolio. Comparable in hospital-channel focus, public payer exposure, and large multi-therapeutic footprint in Spain.
• Bayer España: Spanish operations of Bayer with pharmaceutical (Nubeqa, Eylea, oncology), consumer health, and crop science divisions. Closely comparable in hospital-channel specialty pharma and ophthalmology (Eylea competes directly with Roche's ophthalmology franchise).
• Janssen España (Johnson & Johnson Innovative Medicine): Spanish pharmaceutical arm of Johnson & Johnson with oncology (Darzalex, Erleada), hematology, and immunology franchises. Direct competitor to Roche Farma in multiple myeloma, prostate cancer, and immunology adjacencies.
• AstraZeneca España: Spanish arm of AstraZeneca, with a heavy oncology and biopharmaceutical focus (Imfinzi, Tagrisso, Enhertu). Competes directly with Roche Farma in lung cancer, breast cancer, and hematology, and shares the same hospital channel and NHS Spain reimbursement dynamics.
• Novartis España: Spanish subsidiary of Novartis, a global pharmaceutical leader with strong overlap in oncology, neuroscience, and ophthalmology. Closely comparable to Roche Farma in therapeutic area mix, Spanish public payer exposure, and field-sales-driven commercial model.
• Pfizer España: Spanish operations of Pfizer, one of the largest global pharma companies, with overlapping oncology and hematology franchises (e.g., Ibrance, Padcev, oncology biosimilars). Closely comparable in scale, NHS exposure, and multi-therapeutic commercial model.
• AbbVie España: Spanish subsidiary of AbbVie with oncology, hematology, and neuroscience franchises (Imbruvica, Venclexta, Skyrizi). Direct overlap with Roche Farma in hematology (DLBCL, FL) and immunology, with comparable hospital-channel GTM and biosimilar-exposure dynamics.
• Sanofi España: Spanish operations of Sanofi with strong diabetes, oncology (Sarclisa), and rare disease franchises. Comparable in patient-association engagement, NHS payer exposure, and multi-therapeutic area commercial model.
• GSK España: Spanish arm of GSK with oncology (Jemperli, Blenrep legacy), vaccines, and specialty pharma. Comparable in NHS payer exposure, hospital-channel distribution, and multi-therapeutic commercial model in Spain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/roche_es
• YouTubeyoutube.com/channel/UCuoGlY9iETvmqY3YjSp1EpQ/videos
• Facebookfacebook.com/RocheSpain
• LinkedInlinkedin.com/company/rocheespana
• Instagraminstagram.com/roche_es

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Farma